Status:
COMPLETED
An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States
Lead Sponsor:
Novartis
Conditions:
Parkinson's Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off. This study is not recruiti...
Detailed Description
The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off.
Eligibility Criteria
Inclusion
- Attended the Phase IIb study
- Able to fill out the patient diary
Exclusion
- Serious heart, pulmonary, renal, hepatic or gastrointestinal disease
- Dementia symptoms
- Pregnant or nursing (lactating) women
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
285 Patients enrolled
Trial Details
Trial ID
NCT00237263
Start Date
February 1 2003
End Date
July 1 2007
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936